{"transactions":[{"id":4615913,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-11T20:26:04.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":11939,"price":15.95,"value":190427.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange."}],"balance_after":588848,"source":{"system":"sec-edgar","filing":"0001600620-26-000068","document":"wk-form4_1789158362.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837798/000160062026000068/wk-form4_1789158362.xml","form_type":"4"}},{"id":675843,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-26T01:29:28.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":20975,"price":16.97,"value":355945.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 360 common shares that were acquired on May 29, 2026 by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan."}],"balance_after":600787,"source":{"system":"sec-edgar","filing":"0001837798-26-000013","document":"wk-form4_1787707766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000183779826000013/wk-form4_1787707766.xml","form_type":"4"}},{"id":745879,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-08T20:14:03.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":23931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":23931,"derivative":{"exercise_price":15.67,"expiration_date":"2036-06-04","underlying":"Common Shares","underlying_shares":23931},"source":{"system":"sec-edgar","filing":"0001370348-26-000002","document":"wk-form4_1780949641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000137034826000002/wk-form4_1780949641.xml","form_type":"4"}},{"id":746460,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40559,"kind":"person","name":"Goetz Kathleen","position":1,"cik":"0001896369","reported_name":"Goetz Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-08T20:12:06.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":23931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":23931,"derivative":{"exercise_price":15.67,"expiration_date":"2036-06-04","underlying":"Common Shares","underlying_shares":23931},"source":{"system":"sec-edgar","filing":"0001896369-26-000002","document":"wk-form4_1780949524.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896369/000189636926000002/wk-form4_1780949524.xml","form_type":"4"}},{"id":746030,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40442,"kind":"person","name":"Nova Tina Susan","position":1,"cik":"0001302605","reported_name":"Nova Tina Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-08T20:10:54.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":23931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":23931,"derivative":{"exercise_price":15.67,"expiration_date":"2036-06-04","underlying":"Common Shares","underlying_shares":23931},"source":{"system":"sec-edgar","filing":"0001302605-26-000002","document":"wk-form4_1780949446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302605/000130260526000002/wk-form4_1780949446.xml","form_type":"4"}},{"id":746138,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40463,"kind":"person","name":"Bailey Jeffrey Allen","position":1,"cik":"0001500210","reported_name":"Bailey Jeffrey Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-08T20:08:50.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":23931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":23931,"derivative":{"exercise_price":15.67,"expiration_date":"2036-06-04","underlying":"Common Shares","underlying_shares":23931},"source":{"system":"sec-edgar","filing":"0001500210-26-000002","document":"wk-form4_1780949328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500210/000150021026000002/wk-form4_1780949328.xml","form_type":"4"}},{"id":755393,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Short Put Options (potential obligation to buy)","published_at":"2026-06-03T01:54:36.000Z","date":"2026-06-02","kind":"other","planned":false,"acquired":true,"shares":10000,"price":1.65,"value":16500.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each put option is exercisable only at the option of the counterparty through the expiration date of the put option."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027."}],"balance_after":10000,"derivative":{"exercise_price":15,"exercise_date":"2026-06-02","expiration_date":"2027-01-15","underlying":"Common Shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001178579-26-000004","document":"form4-06032026_010631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000004/form4-06032026_010631.xml","form_type":"4"}},{"id":755392,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T01:54:36.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":206005,"price":15.28,"value":3147756.4,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were purchased in multiple transactions ranging from $15.00 to $15.40."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the \"Funds\")."}],"balance_after":13044106,"source":{"system":"sec-edgar","filing":"0001178579-26-000004","document":"form4-06032026_010631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000004/form4-06032026_010631.xml","form_type":"4"}},{"id":755391,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T01:54:36.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":99,"price":15.34,"value":1518.66,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased at $15.34."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the \"Funds\")."}],"balance_after":12838101,"source":{"system":"sec-edgar","filing":"0001178579-26-000004","document":"form4-06032026_010631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000004/form4-06032026_010631.xml","form_type":"4"}},{"id":755390,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T01:54:36.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":343521,"price":15.28,"value":5249000.88,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions ranging from $14.97 to $15.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the \"Funds\")."}],"balance_after":12838002,"source":{"system":"sec-edgar","filing":"0001178579-26-000004","document":"form4-06032026_010631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000004/form4-06032026_010631.xml","form_type":"4"}},{"id":755389,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T01:54:36.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":262682,"price":15.31,"value":4021661.42,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $15.05 to $15.37."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the \"Funds\")."}],"balance_after":12494481,"source":{"system":"sec-edgar","filing":"0001178579-26-000004","document":"form4-06032026_010631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000004/form4-06032026_010631.xml","form_type":"4"}},{"id":755388,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":18815,"kind":"organization","name":"TANG CAPITAL MANAGEMENT LLC","position":2,"cik":"0001232621","reported_name":"TANG CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-03T01:54:36.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":2299,"price":15.35,"value":35289.65,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. (\"TCP IV\") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the \"Funds\")."}],"balance_after":12231799,"source":{"system":"sec-edgar","filing":"0001178579-26-000004","document":"form4-06032026_010631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000004/form4-06032026_010631.xml","form_type":"4"}},{"id":769597,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-20T21:05:22.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":115541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one common share of the Issuer. 115,541 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date."}],"balance_after":621402,"source":{"system":"sec-edgar","filing":"0001837798-26-000005","document":"wk-form4_1779311116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000183779826000005/wk-form4_1779311116.xml","form_type":"4"}},{"id":769594,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-20T21:04:48.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":70230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly\ninstallments over the following 2 years."}],"balance_after":70230,"derivative":{"exercise_price":15.28,"expiration_date":"2036-05-18","underlying":"Common Stock","underlying_shares":70230},"source":{"system":"sec-edgar","filing":"0001759910-26-000004","document":"wk-form4_1779311085.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000175991026000004/wk-form4_1779311085.xml","form_type":"4"}},{"id":769593,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":45594,"kind":"person","name":"Hearne Michael S","position":1,"cik":"0001759910","reported_name":"Hearne Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-20T21:04:48.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":116144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date."}],"balance_after":116144,"source":{"system":"sec-edgar","filing":"0001759910-26-000004","document":"wk-form4_1779311085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000175991026000004/wk-form4_1779311085.xml","form_type":"4"}},{"id":769592,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":45593,"kind":"person","name":"Cole Ryan","position":1,"cik":"0002126966","reported_name":"Cole Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-20T21:03:50.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":70230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years."}],"balance_after":70230,"derivative":{"exercise_price":15.28,"expiration_date":"2036-05-18","underlying":"Common Stock","underlying_shares":70230},"source":{"system":"sec-edgar","filing":"0002126966-26-000003","document":"wk-form4_1779311027.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000212696626000003/wk-form4_1779311027.xml","form_type":"4"}},{"id":769591,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":45593,"kind":"person","name":"Cole Ryan","position":1,"cik":"0002126966","reported_name":"Cole Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T21:03:50.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":116144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date."}],"balance_after":116144,"source":{"system":"sec-edgar","filing":"0002126966-26-000003","document":"wk-form4_1779311027.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000212696626000003/wk-form4_1779311027.xml","form_type":"4"}},{"id":851494,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-10T20:25:53.000Z","date":"2026-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":8069,"price":14.32,"value":115548.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":154449,"source":{"system":"sec-edgar","filing":"0001600620-26-000024","document":"wk-form4_1773174347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062026000024/wk-form4_1773174347.xml","form_type":"4"}},{"id":869219,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-03T22:35:12.000Z","date":"2026-03-03","kind":"purchase","planned":false,"acquired":true,"shares":184208,"price":14.22,"value":2619437.76,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were purchased in multiple transactions ranging from $13.97 to $14.39."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,990,461 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":12229500,"source":{"system":"sec-edgar","filing":"0001178579-26-000001","document":"form4-03032026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000001/form4-03032026_100309.xml","form_type":"4"}},{"id":869218,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-03T22:35:12.000Z","date":"2026-03-02","kind":"purchase","planned":false,"acquired":true,"shares":115792,"price":14.21,"value":1645404.32,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were purchased in multiple transactions ranging from $14.14 to $14.33."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,990,461 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":12045292,"source":{"system":"sec-edgar","filing":"0001178579-26-000001","document":"form4-03032026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000001/form4-03032026_100309.xml","form_type":"4"}},{"id":869217,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-03T22:35:12.000Z","date":"2026-03-02","kind":"purchase","planned":false,"acquired":true,"shares":83561,"price":14.33,"value":1197429.13,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased in multiple transactions ranging from $14.04 to $14.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,990,461 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11929500,"source":{"system":"sec-edgar","filing":"0001178579-26-000001","document":"form4-03032026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000001/form4-03032026_100309.xml","form_type":"4"}},{"id":869216,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-03T22:35:12.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":1600,"price":14.38,"value":23008.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions ranging from $14.35 to $14.61."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,990,461 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11845939,"source":{"system":"sec-edgar","filing":"0001178579-26-000001","document":"form4-03032026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000001/form4-03032026_100309.xml","form_type":"4"}},{"id":869215,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-03T22:35:12.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":214839,"price":14.12,"value":3033526.68,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $14.00 to $14.18."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,990,461 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11844339,"source":{"system":"sec-edgar","filing":"0001178579-26-000001","document":"form4-03032026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000001/form4-03032026_100309.xml","form_type":"4"}},{"id":869214,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-03T22:35:12.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":13.9,"value":4170000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.51 to $14.23. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 7."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,990,461 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11629500,"source":{"system":"sec-edgar","filing":"0001178579-26-000001","document":"form4-03032026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000117857926000001/form4-03032026_100309.xml","form_type":"4"}},{"id":865241,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:14:36.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":95700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":95700,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":95700},"source":{"system":"sec-edgar","filing":"0001600620-26-000023","document":"wk-form4_1772572473.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000023/wk-form4_1772572473.xml","form_type":"4"}},{"id":865240,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:14:36.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":37511,"price":14.21,"value":533031.31,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":576421,"source":{"system":"sec-edgar","filing":"0001600620-26-000023","document":"wk-form4_1772572473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000023/wk-form4_1772572473.xml","form_type":"4"}},{"id":865239,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:14:36.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":57229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":613932,"source":{"system":"sec-edgar","filing":"0001600620-26-000023","document":"wk-form4_1772572473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000023/wk-form4_1772572473.xml","form_type":"4"}},{"id":865238,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:14:15.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":97256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":97256,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":97256},"source":{"system":"sec-edgar","filing":"0001600620-26-000022","document":"wk-form4_1772572450.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000022/wk-form4_1772572450.xml","form_type":"4"}},{"id":865237,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:14:15.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":40761,"price":14.21,"value":579213.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":680299,"source":{"system":"sec-edgar","filing":"0001600620-26-000022","document":"wk-form4_1772572450.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000022/wk-form4_1772572450.xml","form_type":"4"}},{"id":865236,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:14:15.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":58160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":721060,"source":{"system":"sec-edgar","filing":"0001600620-26-000022","document":"wk-form4_1772572450.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000022/wk-form4_1772572450.xml","form_type":"4"}},{"id":865752,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:13:51.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":328424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":328424,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":328424},"source":{"system":"sec-edgar","filing":"0001600620-26-000021","document":"wk-form4_1772572423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000021/wk-form4_1772572423.xml","form_type":"4"}},{"id":865751,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:13:51.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":100890,"price":14.21,"value":1433646.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":1840379,"source":{"system":"sec-edgar","filing":"0001600620-26-000021","document":"wk-form4_1772572423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000021/wk-form4_1772572423.xml","form_type":"4"}},{"id":865750,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:13:51.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":196403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":1941269,"source":{"system":"sec-edgar","filing":"0001600620-26-000021","document":"wk-form4_1772572423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000021/wk-form4_1772572423.xml","form_type":"4"}},{"id":868938,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:13:25.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":67870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":67870,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":67870},"source":{"system":"sec-edgar","filing":"0001600620-26-000020","document":"wk-form4_1772572400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062026000020/wk-form4_1772572400.xml","form_type":"4"}},{"id":868937,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:13:25.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":40586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":162518,"source":{"system":"sec-edgar","filing":"0001600620-26-000020","document":"wk-form4_1772572400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062026000020/wk-form4_1772572400.xml","form_type":"4"}},{"id":865235,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-03T21:12:57.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":98813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":98813,"derivative":{"exercise_price":13.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":98813},"source":{"system":"sec-edgar","filing":"0001600620-26-000019","document":"wk-form4_1772572374.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000019/wk-form4_1772572374.xml","form_type":"4"}},{"id":865234,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-03-03T21:12:57.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":36525,"price":14.21,"value":519020.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":505861,"source":{"system":"sec-edgar","filing":"0001600620-26-000019","document":"wk-form4_1772572374.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000019/wk-form4_1772572374.xml","form_type":"4"}},{"id":865233,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-03-03T21:12:57.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":59090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":542386,"source":{"system":"sec-edgar","filing":"0001600620-26-000019","document":"wk-form4_1772572374.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000019/wk-form4_1772572374.xml","form_type":"4"}},{"id":887487,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:08:05.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":32901,"price":14.4,"value":473774.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":662900,"source":{"system":"sec-edgar","filing":"0001636642-26-000002","document":"wk-form4_1771880882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000163664226000002/wk-form4_1771880882.xml","form_type":"4"}},{"id":887658,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:07:03.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":100171,"price":14.4,"value":1442462.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":1744866,"source":{"system":"sec-edgar","filing":"0001363683-26-000002","document":"wk-form4_1771880820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000136368326000002/wk-form4_1771880820.xml","form_type":"4"}},{"id":887486,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:05:56.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":32424,"price":14.4,"value":466905.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":556703,"source":{"system":"sec-edgar","filing":"0001746372-26-000002","document":"wk-form4_1771880754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000174637226000002/wk-form4_1771880754.xml","form_type":"4"}},{"id":887484,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-02-23T21:04:33.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":34638,"price":14.4,"value":498787.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":483296,"source":{"system":"sec-edgar","filing":"0001837798-26-000002","document":"wk-form4_1771880670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000183779826000002/wk-form4_1771880670.xml","form_type":"4"}},{"id":922356,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:49:18.000Z","date":"2026-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":11552,"price":14.53,"value":167850.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":121932,"source":{"system":"sec-edgar","filing":"0002044006-26-000002","document":"wk-form4_1770155355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000204400626000002/wk-form4_1770155355.xml","form_type":"4"}},{"id":950028,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-01-05T21:13:30.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":40385,"price":15.95,"value":644140.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 531 common shares were acquired on May 30, 2025 and 354\ncommon shares were acquired on November 28, 2025."}],"balance_after":517934,"source":{"system":"sec-edgar","filing":"0001600620-26-000005","document":"wk-form4_1767647607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000005/wk-form4_1767647607.xml","form_type":"4"}},{"id":950027,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-01-05T21:13:30.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":48558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026."}],"balance_after":557434,"source":{"system":"sec-edgar","filing":"0001600620-26-000005","document":"wk-form4_1767647607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000005/wk-form4_1767647607.xml","form_type":"4"}},{"id":950024,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:12:08.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":42787,"price":15.95,"value":682452.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 30, 2025 and 1,457\ncommon shares were acquired on November 28, 2025."}],"balance_after":695801,"source":{"system":"sec-edgar","filing":"0001600620-26-000004","document":"wk-form4_1767647524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000004/wk-form4_1767647524.xml","form_type":"4"}},{"id":950023,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:12:08.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":54166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026."}],"balance_after":734631,"source":{"system":"sec-edgar","filing":"0001600620-26-000004","document":"wk-form4_1767647524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000004/wk-form4_1767647524.xml","form_type":"4"}},{"id":950026,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:11:21.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":40161,"price":15.95,"value":640567.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,721 common shares were acquired on May 30, 2025 and 1,168\ncommon shares were acquired on November 28, 2025."}],"balance_after":589127,"source":{"system":"sec-edgar","filing":"0001600620-26-000003","document":"wk-form4_1767647470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000003/wk-form4_1767647470.xml","form_type":"4"}},{"id":950025,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:11:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":49038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026."}],"balance_after":626399,"source":{"system":"sec-edgar","filing":"0001600620-26-000003","document":"wk-form4_1767647470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000003/wk-form4_1767647470.xml","form_type":"4"}},{"id":950457,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:10:03.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":113169,"price":15.95,"value":1805045.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,257 common shares were acquired on May 30, 2025 and 1,620\ncommon shares were acquired on November 28, 2025."}],"balance_after":1845037,"source":{"system":"sec-edgar","filing":"0001600620-26-000002","document":"wk-form4_1767647395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000002/wk-form4_1767647395.xml","form_type":"4"}},{"id":950456,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:10:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":165384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026."}],"balance_after":1954329,"source":{"system":"sec-edgar","filing":"0001600620-26-000002","document":"wk-form4_1767647395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062026000002/wk-form4_1767647395.xml","form_type":"4"}},{"id":989957,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40463,"kind":"person","name":"Bailey Jeffrey Allen","position":1,"cik":"0001500210","reported_name":"Bailey Jeffrey Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-24T22:19:15.000Z","date":"2025-11-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":2716,"price":15.68,"value":42586.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":22775,"source":{"system":"sec-edgar","filing":"0001600620-25-000110","document":"wk-form4_1764022752.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500210/000160062025000110/wk-form4_1764022752.xml","form_type":"4"}},{"id":989738,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-24T22:17:53.000Z","date":"2025-11-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":6039,"price":15.68,"value":94691.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":14592,"source":{"system":"sec-edgar","filing":"0001370348-25-000004","document":"wk-form4_1764022670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000137034825000004/wk-form4_1764022670.xml","form_type":"4"}},{"id":1075074,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-08-05T21:31:03.000Z","date":"2025-08-05","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":11.68,"value":2336000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions ranging from $11.49 to $11.80."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,371,711 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11329500,"source":{"system":"sec-edgar","filing":"0001415889-25-021066","document":"form4-08052025_090800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925021066/form4-08052025_090800.xml","form_type":"4"}},{"id":1075073,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-08-05T21:31:03.000Z","date":"2025-08-04","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":11.34,"value":1134000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions ranging from $11.11 to $11.48."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,371,711 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11129500,"source":{"system":"sec-edgar","filing":"0001415889-25-021066","document":"form4-08052025_090800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925021066/form4-08052025_090800.xml","form_type":"4"}},{"id":1075072,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-08-05T21:31:03.000Z","date":"2025-08-01","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":10.12,"value":10120000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $9.23 to $10.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 6,371,711 shares and  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI."}],"balance_after":11029500,"source":{"system":"sec-edgar","filing":"0001415889-25-021066","document":"form4-08052025_090800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925021066/form4-08052025_090800.xml","form_type":"4"}},{"id":1075053,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-05T20:07:28.000Z","date":"2025-08-01","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":10.5,"value":210000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $10.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":133484,"source":{"system":"sec-edgar","filing":"0001600620-25-000095","document":"wk-form4_1754424444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062025000095/wk-form4_1754424444.xml","form_type":"4"}},{"id":1145150,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40442,"kind":"person","name":"Nova Tina Susan","position":1,"cik":"0001302605","reported_name":"Nova Tina Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-16T21:06:05.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":63724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":63724,"derivative":{"exercise_price":8.15,"expiration_date":"2035-05-16","underlying":"Common Shares","underlying_shares":63724},"source":{"system":"sec-edgar","filing":"0001600620-25-000078","document":"wk-form4_1747429558.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302605/000160062025000078/wk-form4_1747429558.xml","form_type":"4"}},{"id":1144954,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-16T21:05:19.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":37485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":37485,"derivative":{"exercise_price":8.15,"expiration_date":"2035-05-16","underlying":"Common Shares","underlying_shares":37485},"source":{"system":"sec-edgar","filing":"0001600620-25-000077","document":"wk-form4_1747429513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000160062025000077/wk-form4_1747429513.xml","form_type":"4"}},{"id":1145663,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40559,"kind":"person","name":"Goetz Kathleen","position":1,"cik":"0001896369","reported_name":"Goetz Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-16T21:04:45.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":63724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":63724,"derivative":{"exercise_price":8.15,"expiration_date":"2035-05-16","underlying":"Common Shares","underlying_shares":63724},"source":{"system":"sec-edgar","filing":"0001600620-25-000076","document":"wk-form4_1747429477.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896369/000160062025000076/wk-form4_1747429477.xml","form_type":"4"}},{"id":1145342,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40463,"kind":"person","name":"Bailey Jeffrey Allen","position":1,"cik":"0001500210","reported_name":"Bailey Jeffrey Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-16T21:04:19.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":37485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":37485,"derivative":{"exercise_price":8.15,"expiration_date":"2035-05-16","underlying":"Common Shares","underlying_shares":37485},"source":{"system":"sec-edgar","filing":"0001600620-25-000075","document":"wk-form4_1747429452.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500210/000160062025000075/wk-form4_1747429452.xml","form_type":"4"}},{"id":1217850,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-07T22:25:05.000Z","date":"2025-03-07","kind":"sale","planned":false,"acquired":false,"shares":8305,"price":8.23,"value":68350.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 6, 2023 grant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":153484,"source":{"system":"sec-edgar","filing":"0001600620-25-000026","document":"wk-form4_1741386297.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062025000026/wk-form4_1741386297.xml","form_type":"4"}},{"id":1227103,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T02:02:08.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":443973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":443973,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":443973},"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227102,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":164947,"price":7.92,"value":1306380.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1788945,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227101,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":195593,"price":8,"value":1564744.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1953892,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227100,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":333705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025."}],"balance_after":2149485,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1227099,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T02:02:08.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":290728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024."}],"balance_after":1815780,"source":{"system":"sec-edgar","filing":"0001600620-25-000024","document":"wk-form4_1741140121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000160062025000024/wk-form4_1741140121.xml","form_type":"4"}},{"id":1230191,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T01:59:49.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":95570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":95570,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":95570},"source":{"system":"sec-edgar","filing":"0001600620-25-000022","document":"wk-form4_1741139983.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062025000022/wk-form4_1741139983.xml","form_type":"4"}},{"id":1230190,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:59:49.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":12239,"price":8,"value":97912.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the January 30, 2024 grant."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":161789,"source":{"system":"sec-edgar","filing":"0001600620-25-000022","document":"wk-form4_1741139983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062025000022/wk-form4_1741139983.xml","form_type":"4"}},{"id":1230189,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":29016,"kind":"person","name":"Keenan Greg","position":1,"cik":"0002044006","reported_name":"Keenan Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:59:49.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":62583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."}],"balance_after":174028,"source":{"system":"sec-edgar","filing":"0001600620-25-000022","document":"wk-form4_1741139983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044006/000160062025000022/wk-form4_1741139983.xml","form_type":"4"}},{"id":1226427,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T01:58:10.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":124393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":124393,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":124393},"source":{"system":"sec-edgar","filing":"0001600620-25-000020","document":"wk-form4_1741139883.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000020/wk-form4_1741139883.xml","form_type":"4"}},{"id":1226426,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:58:10.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":56154,"price":7.92,"value":444739.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the\nIssuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":577361,"source":{"system":"sec-edgar","filing":"0001600620-25-000020","document":"wk-form4_1741139883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000020/wk-form4_1741139883.xml","form_type":"4"}},{"id":1226425,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:58:10.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":61859,"price":8,"value":494872.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":633515,"source":{"system":"sec-edgar","filing":"0001600620-25-000020","document":"wk-form4_1741139883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000020/wk-form4_1741139883.xml","form_type":"4"}},{"id":1226424,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:58:10.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":114711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025."}],"balance_after":695374,"source":{"system":"sec-edgar","filing":"0001600620-25-000020","document":"wk-form4_1741139883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000020/wk-form4_1741139883.xml","form_type":"4"}},{"id":1226423,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63148,"kind":"person","name":"Miller Joseph M","position":1,"cik":"0001746372","reported_name":"Miller Joseph M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:58:10.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":81457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,630 common shares were acquired on May 31, 2024 and 1,648 common shares were acquired on November 29, 2024."}],"balance_after":580663,"source":{"system":"sec-edgar","filing":"0001600620-25-000020","document":"wk-form4_1741139883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000020/wk-form4_1741139883.xml","form_type":"4"}},{"id":1226422,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T01:57:21.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":128438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":128438,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":128438},"source":{"system":"sec-edgar","filing":"0001600620-25-000019","document":"wk-form4_1741139835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000019/wk-form4_1741139835.xml","form_type":"4"}},{"id":1226421,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-05T01:57:21.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":57607,"price":7.92,"value":456247.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":509276,"source":{"system":"sec-edgar","filing":"0001600620-25-000019","document":"wk-form4_1741139835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000019/wk-form4_1741139835.xml","form_type":"4"}},{"id":1226420,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-05T01:57:21.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":64872,"price":8,"value":518976.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance\naward."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the\nIssuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":566883,"source":{"system":"sec-edgar","filing":"0001600620-25-000019","document":"wk-form4_1741139835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000019/wk-form4_1741139835.xml","form_type":"4"}},{"id":1226419,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-05T01:57:21.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":102406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025."}],"balance_after":631755,"source":{"system":"sec-edgar","filing":"0001600620-25-000019","document":"wk-form4_1741139835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000019/wk-form4_1741139835.xml","form_type":"4"}},{"id":1226418,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":19812,"kind":"person","name":"Robertson Stephen P.","position":1,"cik":"0001837798","reported_name":"Robertson Stephen P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-05T01:57:21.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":84106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 513 common shares were acquired on May 31, 2024 and 506 common shares were acquired on November 29, 2024."}],"balance_after":529349,"source":{"system":"sec-edgar","filing":"0001600620-25-000019","document":"wk-form4_1741139835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000019/wk-form4_1741139835.xml","form_type":"4"}},{"id":1226405,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-05T01:56:40.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":126416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter."}],"balance_after":126416,"derivative":{"exercise_price":7.55,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":126416},"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226404,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":58991,"price":7.92,"value":467208.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":680465,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226403,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":65902,"price":8,"value":527216.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":739456,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226402,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":135567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025."}],"balance_after":805358,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1226401,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":63147,"kind":"person","name":"Donley Matthew Maxwell","position":1,"cik":"0001636642","reported_name":"Donley Matthew Maxwell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-05T01:56:40.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":82781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four\nprogressively higher target prices, with respective one year retention periods per tranche achievement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024."}],"balance_after":669791,"source":{"system":"sec-edgar","filing":"0001600620-25-000018","document":"wk-form4_1741139793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000018/wk-form4_1741139793.xml","form_type":"4"}},{"id":1230393,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-03-04T22:03:02.000Z","date":"2025-03-04","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":8.09,"value":809000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were purchased in multiple transactions at prices ranging from $8.05 to $8.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 5,140,591 shares,  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III."}],"balance_after":10029500,"source":{"system":"sec-edgar","filing":"0001415889-25-006589","document":"form4-03042025_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925006589/form4-03042025_100358.xml","form_type":"4"}},{"id":1230392,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-03-04T22:03:02.000Z","date":"2025-03-04","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":7.92,"value":3960000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were purchased in multiple transactions at prices ranging from $7.76 to $8.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 5,140,591 shares,  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III."}],"balance_after":9929500,"source":{"system":"sec-edgar","filing":"0001415889-25-006589","document":"form4-03042025_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925006589/form4-03042025_100358.xml","form_type":"4"}},{"id":1230391,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-03-04T22:03:02.000Z","date":"2025-03-04","kind":"purchase","planned":false,"acquired":true,"shares":148038,"price":8,"value":1184304.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased in multiple transactions at prices ranging from $7.82 to $8.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 5,140,591 shares,  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III."}],"balance_after":9429500,"source":{"system":"sec-edgar","filing":"0001415889-25-006589","document":"form4-03042025_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925006589/form4-03042025_100358.xml","form_type":"4"}},{"id":1230390,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-03-04T22:03:02.000Z","date":"2025-03-03","kind":"purchase","planned":false,"acquired":true,"shares":351962,"price":8.02,"value":2822735.24,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 5,140,591 shares,  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III."}],"balance_after":9281462,"source":{"system":"sec-edgar","filing":"0001415889-25-006589","document":"form4-03042025_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925006589/form4-03042025_100358.xml","form_type":"4"}},{"id":1230389,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-03-04T22:03:02.000Z","date":"2025-03-03","kind":"purchase","planned":false,"acquired":true,"shares":100720,"price":7.97,"value":802738.4,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.05."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 5,140,591 shares,  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III."}],"balance_after":8929500,"source":{"system":"sec-edgar","filing":"0001415889-25-006589","document":"form4-03042025_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925006589/form4-03042025_100358.xml","form_type":"4"}},{"id":1230388,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-03-04T22:03:02.000Z","date":"2025-02-28","kind":"purchase","planned":false,"acquired":true,"shares":399280,"price":7.85,"value":3134348.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $7.47 to $7.95. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, and 3 through 7."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 5,140,591 shares,  Tang Capital Partners International, LP (\"TCPI\") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III."}],"balance_after":8828780,"source":{"system":"sec-edgar","filing":"0001415889-25-006589","document":"form4-03042025_100358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588925006589/form4-03042025_100358.xml","form_type":"4"}},{"id":1339322,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-12-09T21:52:50.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":9.09,"value":4545000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.19."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,929,500 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCP III."}],"balance_after":8429500,"source":{"system":"sec-edgar","filing":"0001415889-24-028661","document":"form4-12092024_091246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924028661/form4-12092024_091246.xml","form_type":"4"}},{"id":1339321,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-12-09T21:52:50.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":9.01,"value":3604000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.15."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,929,500 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCP III."}],"balance_after":7929500,"source":{"system":"sec-edgar","filing":"0001415889-24-028661","document":"form4-12092024_091246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924028661/form4-12092024_091246.xml","form_type":"4"}},{"id":1339320,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":18814,"kind":"person","name":"TANG KEVIN","position":1,"cik":"0001178579","reported_name":"TANG KEVIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-12-09T21:52:50.000Z","date":"2024-12-05","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":8.91,"value":2673000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $8.74 to $8.99. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Tang Capital Partners, LP (\"TCP\") beneficially owns 7,929,500 shares and Tang Capital Partners III, Inc. (\"TCP III\") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC (\"TCM\"), which is the general partner of TCP. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCP III."}],"balance_after":7529500,"source":{"system":"sec-edgar","filing":"0001415889-24-028661","document":"form4-12092024_091246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178579/000141588924028661/form4-12092024_091246.xml","form_type":"4"}},{"id":1352337,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-11-25T21:38:58.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":18641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest one year from date of grant."}],"balance_after":18641,"derivative":{"exercise_price":8.24,"expiration_date":"2034-11-21","underlying":"Common Shares","underlying_shares":18641},"source":{"system":"sec-edgar","filing":"0001600620-24-000126","document":"wk-form4_1732570731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000126/wk-form4_1732570731.xml","form_type":"4"}},{"id":1352336,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:38:58.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":12135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant."}],"balance_after":24807,"source":{"system":"sec-edgar","filing":"0001600620-24-000126","document":"wk-form4_1732570731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000126/wk-form4_1732570731.xml","form_type":"4"}},{"id":1352335,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":85667,"kind":"person","name":"Leversage Jill","position":1,"cik":"0001837374","reported_name":"Leversage Jill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-11-25T21:36:36.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":18641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest one year from date of grant."}],"balance_after":18641,"derivative":{"exercise_price":8.24,"expiration_date":"2034-11-21","underlying":"Common Shares","underlying_shares":18641},"source":{"system":"sec-edgar","filing":"0001600620-24-000124","document":"wk-form4_1732570590.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000124/wk-form4_1732570590.xml","form_type":"4"}},{"id":1352334,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":85667,"kind":"person","name":"Leversage Jill","position":1,"cik":"0001837374","reported_name":"Leversage Jill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:36:36.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":12135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant."}],"balance_after":25053,"source":{"system":"sec-edgar","filing":"0001600620-24-000124","document":"wk-form4_1732570590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000124/wk-form4_1732570590.xml","form_type":"4"}},{"id":1352409,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-11-25T21:33:38.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":31688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest one year from date of grant."}],"balance_after":31688,"derivative":{"exercise_price":8.24,"expiration_date":"2034-11-21","underlying":"Common Shares","underlying_shares":31688},"source":{"system":"sec-edgar","filing":"0001600620-24-000122","document":"wk-form4_1732570412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000160062024000122/wk-form4_1732570412.xml","form_type":"4"}},{"id":1352408,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:33:38.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":20631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant."}],"balance_after":20631,"source":{"system":"sec-edgar","filing":"0001600620-24-000122","document":"wk-form4_1732570412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000160062024000122/wk-form4_1732570412.xml","form_type":"4"}}],"next_cursor":"2024-11-25T21:33:38.000000Z,1352408"}